NYMXF — Nymox Pharmaceutical Balance Sheet
0.000.00%
- $8.44m
- $8.40m
Annual balance sheet for Nymox Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 5.24 | 3.61 | 0.83 | 1.4 | 0.07 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.018 | 0.02 | 0.013 | 0.01 | 0.011 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5.33 | 3.89 | 1.04 | 1.46 | 0.625 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.161 | 0.45 | 0.406 | 0.168 | 0.002 |
Other Long Term Assets | |||||
Total Assets | 5.49 | 4.34 | 1.44 | 1.63 | 0.627 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.04 | 1.83 | 1.79 | 2.11 | 3.8 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.04 | 2.2 | 1.95 | 2.11 | 3.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 3.45 | 2.15 | -0.506 | -0.482 | -3.17 |
Total Liabilities & Shareholders' Equity | 5.49 | 4.34 | 1.44 | 1.63 | 0.627 |
Total Common Shares Outstanding |